Review of EU clinical trials framework on track; directive to be replaced with regulation
This article was originally published in SRA
The European Commission wants to replace the EU directive on clinical trials – which is currently undergoing revision – with a regulation so as to ensure greater uniformity among member states in implementing the revised provisions, EU commissioner for health and consumer policy John Dalli announced at a 7 March meeting1.
You may also be interested in...
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.